Paper23707609
Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways.
Do MT and 6 others. Toxicol Appl Pharmacol, 2013. Cited by 103 papers, by iCite.
Cite this record
ConductScience Library. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways. Papers, record 23707609. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23707609
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways.
- PubMed
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Heme Oxygenase-1 | Major topic |
| Hypoglycemic Agents | Major topic |
| MAP Kinase Signaling System | Major topic |
| Metformin | Major topic |
| Mitogen-Activated Protein Kinases | Major topic |
| NF-E2-Related Factor 2 | Major topic |
| Neoplasms | Major topic |
| raf Kinases | Major topic |
| Blotting, Western | |
| Cell Line, Tumor | |
| Cell Nucleus | |
| Cell Survival | |
| Cytosol | |
| Galactosidases | |
| Humans | |
| Indicators and Reagents | |
| Luciferases | |
| Plasmids | |
| RNA | |
| RNA, Small Interfering | |
| Real-Time Polymerase Chain Reaction | |
| Signal Transduction | |
| Transfection |
Source PubMed
Cited by59
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 103 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42904151 | Molecular Mechanisms and Signaling Pathways Underlying the Synergistic Effect of Metformin and Paclitaxel in Preclinical Cancer Models: A Systematic Review. | Cancer Manag Res | 2026 | https://conductscience.org/library/papers/42904151 | PubMed |
| 41783405 | Research Progress on the Molecular Mechanism of Metformin Regulating AMPK Signaling Pathway in Inhibiting Liver Cancer. | Onco Targets Ther | 2026 | https://conductscience.org/library/papers/41783405 | PubMed |
| 41470226 | Effects of the Pharmacological Modulation of NRF2 in Cancer Progression. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/41470226 | PubMed |
| 40722961 | Oxidative Stress Defense Module in Lung Cancers: Molecular Pathways and Therapeutic Approaches. | Antioxidants (Basel) | 2025 | https://conductscience.org/library/papers/40722961 | PubMed |
| 40331195 | Metformin in gynecological disorders: pathogenic insights and therapeutic implications. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40331195 | PubMed |
| 40059038 | Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases. | Redox Biol | 2025 | https://conductscience.org/library/papers/40059038 | PubMed |
| 38984567 | The Growth Inhibitory Effect of Resveratrol and Gallic Acid on Prostate Cancer Cell Lines through the Alteration of Oxidative Stress Balance: The Interplay between Nrf2, HO-1, and BACH1 Genes. | Anticancer Agents Med Chem | 2024 | https://conductscience.org/library/papers/38984567 | PubMed |
| 38937794 | Macrophages as determinants and regulators of systemic sclerosis-related interstitial lung disease. | J Transl Med | 2024 | https://conductscience.org/library/papers/38937794 | PubMed |
| 38324554 | Inverse association between total bilirubin and type 2 diabetes in U.S. South Asian males but not females. | PLoS One | 2024 | https://conductscience.org/library/papers/38324554 | PubMed |
| 38059999 | Metformin protects retinal pigment epithelium cells against H2O2-induced oxidative stress and inflammation via the Nrf2 signaling cascade. | Graefes Arch Clin Exp Ophthalmol | 2024 | https://conductscience.org/library/papers/38059999 | PubMed |
| 37883349 | Metformin pretreatment ameliorates busulfan-induced liver endothelial toxicity during haematopoietic stem cell transplantation. | PLoS One | 2023 | https://conductscience.org/library/papers/37883349 | PubMed |
| 37810967 | Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers. | Front Oncol | 2023 | https://conductscience.org/library/papers/37810967 | PubMed |
| 37480500 | The mechanistic insights of the antioxidant Keap1-Nrf2 pathway in oncogenesis: a deadly scenario. | Med Oncol | 2023 | https://conductscience.org/library/papers/37480500 | PubMed |
| 36901764 | A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36901764 | PubMed |
| 36513865 | Dual role of Nrf2 in cancer: molecular mechanisms, cellular functions and therapeutic interventions. | Mol Biol Rep | 2023 | https://conductscience.org/library/papers/36513865 | PubMed |
| 34903525 | Metformin Reduces Repeat Mild Concussive Injury Pathophysiology. | eNeuro | 2022 | https://conductscience.org/library/papers/34903525 | PubMed |
| 34873484 | Dual anticancer role of metformin: an old drug regulating AMPK dependent/independent pathways in metabolic, oncogenic/tumorsuppresing and immunity context. | Am J Cancer Res | 2021 | https://conductscience.org/library/papers/34873484 | PubMed |
| 34589492 | Nrf2 Is a Potential Modulator for Orchestrating Iron Homeostasis and Redox Balance in Cancer Cells. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/34589492 | PubMed |
| 34356353 | Miquelianin Inhibits Allergic Responses in Mice by Suppressing CD4+ T Cell Proliferation. | Antioxidants (Basel) | 2021 | https://conductscience.org/library/papers/34356353 | PubMed |
| 34067321 | Molecular and Cellular Mechanisms of Metformin in Cervical Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34067321 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| HMOX1 | 3162 | PubTator's text mining | https://conductscience.org/library/genes/3162 | NCBI Gene |
| KEAP1 | 9817 | PubTator's text mining | https://conductscience.org/library/genes/9817 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| MAPK3 | 5595 | PubTator's text mining | https://conductscience.org/library/genes/5595 | NCBI Gene |
| NFE2L2 | 4780 | PubTator's text mining | https://conductscience.org/library/genes/4780 | NCBI Gene |
| NQO1 | 1728 | PubTator's text mining | https://conductscience.org/library/genes/1728 | NCBI Gene |
| PRKAA1 | 5562 | PubTator's text mining | https://conductscience.org/library/genes/5562 | NCBI Gene |
| RAF1 | 5894 | PubTator's text mining | https://conductscience.org/library/genes/5894 | NCBI Gene |
| ZHX2 | 22882 | PubTator's text mining | https://conductscience.org/library/genes/22882 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23707609
GET https://conductscience.org/api/papers/v1/23707609/cited_by?page=2